Billionaire entrepreneur Mark Cuban said generic medicines are already competitively priced in the U.S., while pharmacy benefit managers are making it harder for consumers to access cheaper brand-name drugs.

Cuban Targets PBMs

On Tuesday, Cuban made the comments in a post on X while discussing prescription drug prices.

"Actually, our prices on generics are lower than most of the world," Cuban said.

He added, "We get requests to buy from everywhere."

He said his company does not sell many brand-name medicines because Pharmacy Benefit Managers (PBMs) "won’t allow manufacturers to sell to us."

Cuban argued that his company could potentially offer some brand-name drugs at significantly lower prices if manufacturers were able to sell them through his platform.

"For many of those brand meds, if we could sell at our 15% markup, we would be at or near their pricing and in some cases lower," he said.

Cuban then criticized the role of large healthcare companies and PBMs in determining drug prices.

"As long as we let the big conglomerates and their PBMs set pricing, we will always pay more," Cuban said.

He added, "They are Too Big To Care!"

Actually, our prices on generics are lower than most of the world. We get requests to buy from everywhere.

It's the brand drugs we don't sell, because PBMs won't allow manufacturers to sell to us, that are more expensive

For many of those brand meds, if we could sell at our… https://t.co/M6YDjux8nE

— Mark Cuban (@mcuban) August 25, 2026

White House Touted Drug Price Drop

The White House highlighted a 3.1% year-over-year decline in prescription drug prices in July, calling it evidence of President Donald Trump’s success.

However, experts said the drop was more likely driven by Medicare drug-price negotiations established under President Joe Biden’s 2022 Inflation Reduction Act.

Trump promoted the headline, saying, "I told you that was going to happen," while the White House posted, "POV: you bring the receipts."

Drug Prices and Medicare Reform

House Speaker Mike Johnson (R-La.) credited Trump and Republicans for lower prescription drug prices, saying they had fallen to their lowest level in more than 60 years.

A federal court also upheld the Inflation Reduction Act’s Medicare drug-price negotiation program after rejecting Merck’s constitutional challenge.

CMS Administrator Mehmet Oz said the administration plans to extend Medicare’s solvency through drug-price reforms, fraud reduction and AI.

He said 17 pharmaceutical companies representing 85% of the industry had agreed to most-favored-nation pricing and that some Medicare beneficiaries could get GLP-1 drugs for $50 a month, down from more than $1,000.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Shutterstock